Genomind Co-Founder and Neurologist Challenges Conventional Thinking about Brain Disorders
CHALFONT, PA – November 5, 2013 – Dr. Jay Lombard of Genomind, a personalized medicine company, will speak to the challenges of diagnosing and treating brain disorders at the Partnering for Cures Conference in New York City at the Grand Hyatt Hotel November 3-5, 2013. FasterCures is a center of the Milken Institute.
Now in its fifth year, this conference continues to draw medical innovators from across sectors of the research and development ecosystem. This year’s Partnering for Cures program will feature 16 panels addressing mission-critical issues in the life sciences – from innovation to regulation, from drug repositioning to de-risking investments, and from translational research to data networks. Instead of traditional keynote speakers, the panels feature interactive discussions and occasional one-on-one interviews with leading biomedical research innovators. Speakers include philanthropists, industry executives, patient advocates, nonprofit foundations, and academic and industry scientists engaged in some of the most constructively disruptive approaches to research.
Dr. Lombard will discuss the present day challenges in psychiatry, and a solution to the problem – the Genecept™ Assay, Genomind’s saliva-based genetic test that helps clinicians determine a more personalized treatment plan for their patients. He will be featured on a panel with other leaders in the mental health field to include:
- Dr. Thomas Insel, Director of the National Institute of Mental Health
- Robert Ring, Chief Scientific Officer of Autism Speaks
- Paul Weiss, Director of the California NanoSystems Institute
“In our efforts to treat brain disorders, new biomarker tools are emerging to help clinicians identify fundamental pathological mechanisms,” said Dr. Lombard, Chief Scientific Officer and Medical Director of Genomind. “The discovery and utilization of biomarkers in this regard will help clinicians treat these conditions based upon their specific causes, rather than symptomatically as is current practice.”
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.
FasterCures, a center of the Milken Institute, is an ‘action tank’ that works to improve the medical research system – so that we can speed up the time it takes to get important new medicines from discovery to patients. FasterCures works across all sectors and diseases to transform the way we pursue, fund, and conduct medical research. For more information, visit www.fastercures.org.
For more information, contact:
Marketing Manager, Genomind